Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation.

[1]  S. Curbo,et al.  Mitochondrial dysfunction is associated with lipid metabolism disorder and upregulation of angiotensin-converting enzyme 2 , 2022, PloS one.

[2]  Shuangquan Zou,et al.  Flavonoid and chromone-rich extract from Euscaphis Konishii Hayata leaf attenuated alcoholic liver injury in mice. , 2022, Journal of ethnopharmacology.

[3]  Xinyun Cao,et al.  YY1 inactivated transcription co-regulator PGC-1α to promote mitochondrial dysfunction of early diabetic nephropathy-associated tubulointerstitial fibrosis , 2022, Cell Biology and Toxicology.

[4]  Binan Lu,et al.  Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Yu Jiang,et al.  Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications. , 2022, Current drug targets.

[6]  Yongchao Wu,et al.  Liquiritigenin protects against arsenic trioxide-induced liver injury by inhibiting oxidative stress and enhancing mTOR-mediated autophagy. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  Min Suk Shim,et al.  Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 , 2021, International journal of molecular sciences.

[8]  Julia J. Mack,et al.  FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. , 2021, Cell metabolism.

[9]  Xinyue Wu,et al.  The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence , 2021, Oxidative medicine and cellular longevity.

[10]  Mengting Zhou,et al.  Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism , 2021, Phytotherapy research : PTR.

[11]  J. Komorowski,et al.  Multifaceted regulation of hepatic lipid metabolism by YY1 , 2021, Life Science Alliance.

[12]  F. Yoshizawa,et al.  Quercetin enhances fatty acid β-oxidation by inducing lipophagy in AML12 hepatocytes , 2021, Heliyon.

[13]  J. Heeren,et al.  Metabolic-associated fatty liver disease and lipoprotein metabolism , 2021, Molecular metabolism.

[14]  F. García-Carmona,et al.  Flavonoids’ Effects on Caenorhabditis elegans’ Longevity, Fat Accumulation, Stress Resistance and Gene Modulation Involve mTOR, SKN-1 and DAF-16 , 2021, Antioxidants.

[15]  Dingmei Zhang,et al.  Prenatal dexamethasone exposure induces nonalcoholic fatty liver disease in male rat offspring via the miR-122/YY1/ACE2-MAS1 pathway. , 2021, Biochemical pharmacology.

[16]  Zhipeng Xu,et al.  Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro. , 2020, Canadian journal of physiology and pharmacology.

[17]  Mingjie Xie,et al.  Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway , 2020, Aging.

[18]  Zhenzhou Jiang,et al.  Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. , 2020, Food & function.

[19]  Xiaoxin Yin,et al.  Quercetin inhibits AQP1 translocation in high-glucose-cultured SRA01/04 cells through PI3K/Akt/mTOR Pathway. , 2020, Current molecular pharmacology.

[20]  R. Sato.  Recent advances in regulating cholesterol and bile acid metabolism , 2020, Bioscience, biotechnology, and biochemistry.

[21]  A. S. Grewal,et al.  In vitro targeted screening and molecular docking of stilbene, quinones, and flavonoid on 3T3-L1 pre-adipocytes for anti-adipogenic actions , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  M. Roden,et al.  Metabolic liver disease in diabetes – From mechanisms to clinical trials , 2020, Metabolism.

[23]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[24]  G. Ning,et al.  Betulinic acid improves nonalcoholic fatty liver disease through YY1/FAS signaling pathway , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Feihua Wu,et al.  Scutellarin, a modulator of mTOR, attenuates hepatic insulin resistance by regulating hepatocyte lipid metabolism via SREBP‐1c suppression , 2019, Phytotherapy research : PTR.

[26]  Guanbin Song,et al.  Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation , 2019, Theranostics.

[27]  K. Kajo,et al.  Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels , 2019, Biomolecules.

[28]  M. Mohajeri-Tehrani,et al.  The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects. , 2019, Endocrine, metabolic & immune disorders drug targets.

[29]  Zhenzhou Jiang,et al.  Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice , 2019, Phytotherapy research : PTR.

[30]  W. Jia,et al.  Ursodeoxycholic Acid Alters Bile Acid and Fatty Acid Profiles in a Mouse Model of Diet-Induced Obesity , 2019, Front. Pharmacol..

[31]  Xiaoxin Yin,et al.  YY1: A novel therapeutic target for diabetic nephropathy orchestrated renal fibrosis. , 2019, Metabolism: clinical and experimental.

[32]  Yi Hao,et al.  Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway. , 2019, Pharmacological research.

[33]  Y. Liu,et al.  Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer , 2019, International journal of biological sciences.

[34]  A. Bayés‐Genís,et al.  Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. , 2019, Journal of molecular and cellular cardiology.

[35]  Y. Egashira,et al.  The Combination of 'Benifuuki' with Quercetin Suppresses Hepatic Fat Accumulation in High-Fat High-Cholesterol Diet-Fed Rats. , 2019, Journal of nutritional science and vitaminology.

[36]  Jun Sik Lee,et al.  FoxO6-mediated IL-1β induces hepatic insulin resistance and age-related inflammation via the TF/PAR2 pathway in aging and diabetic mice , 2019, Redox biology.

[37]  Rongsheng Tong,et al.  Antidiabetic Potential of Flavonoids from Traditional Chinese Medicine: A Review. , 2019, The American journal of Chinese medicine.

[38]  Luyong Zhang,et al.  Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. , 2019, Drug discovery today.

[39]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[40]  Yitao Ding,et al.  Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery , 2018, BMC Gastroenterology.

[41]  T. Asselah,et al.  Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. , 2018, Gastroenterology.

[42]  L. Lara-Jacobo,et al.  Daily Consumption of a Chocolate Rich in Flavonoids Decreases Cellular Genotoxicity and Improves Biochemical Parameters of Lipid and Glucose Metabolism , 2018 .

[43]  Yanjun Li,et al.  Yin Yang 1 promotes the Warburg effect and tumorigenesis via glucose transporter GLUT3 , 2018, Cancer science.

[44]  Zhuo Mao,et al.  Role of mTOR in Glucose and Lipid Metabolism , 2018, International journal of molecular sciences.

[45]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[46]  A. Hamide,et al.  Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. , 2018, Diabetes & metabolic syndrome.

[47]  M. Miyagishi,et al.  Transcription Factor YY1 Promotes Cell Proliferation by Directly Activating the Pentose Phosphate Pathway. , 2018, Cancer research.

[48]  Yuhan Tang,et al.  Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[49]  M. Uehara,et al.  Flavonoid metabolism: the interaction of metabolites and gut microbiota , 2018, Bioscience, biotechnology, and biochemistry.

[50]  M. Akash,et al.  Tumor Necrosis Factor‐Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus , 2018, Journal of cellular biochemistry.

[51]  Xiaoxin Yin,et al.  Antidiabetic cataract effects of GbE, rutin and quercetin are mediated by the inhibition of oxidative stress and polyol pathway. , 2017, Acta biochimica Polonica.

[52]  Yi-tao Ding,et al.  MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1 , 2017, Cellular Physiology and Biochemistry.

[53]  B. Ni,et al.  Multifunctional YY1 in Liver Diseases , 2017, Seminars in Liver Disease.

[54]  Xiaoxin Yin,et al.  Quercetin inhibited epithelial mesenchymal transition in diabetic rats, high-glucose-cultured lens, and SRA01/04 cells through transforming growth factor-β2/phosphoinositide 3-kinase/Akt pathway , 2017, Molecular and Cellular Endocrinology.

[55]  Luyong Zhang,et al.  Quantitative profiling of 19 bile acids in rat plasma, liver, bile and different intestinal section contents to investigate bile acid homeostasis and the application of temporal variation of endogenous bile acids , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[56]  L. Ding,et al.  Rutin exhibits hepatoprotective effects in a mouse model of non‐alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid‐induced oxidative injuries , 2017, International immunopharmacology.

[57]  B. Staels,et al.  Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. , 2017 .

[58]  Yiguo Wang,et al.  mTORC1 signaling in hepatic lipid metabolism , 2017, Protein & Cell.

[59]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[60]  Robert A. Harris,et al.  Melatonin ameliorates alcohol‐induced bile acid synthesis by enhancing miR‐497 expression , 2017, Journal of pineal research.

[61]  M. Qadir,et al.  Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. , 2017, Critical reviews in eukaryotic gene expression.

[62]  D. Moris,et al.  Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. , 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[63]  Michael Roden,et al.  NAFLD and diabetes mellitus , 2017, Nature Reviews Gastroenterology &Hepatology.

[64]  J. Tomlinson,et al.  Non-alcoholic fatty liver disease and diabetes , 2016, Metabolism: clinical and experimental.

[65]  Zongkai Xie,et al.  Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats. , 2016, Nutrition research.

[66]  Xiao-Jun Ji,et al.  Ethanolic Ginkgo biloba leaf extract prevents renal fibrosis through Akt/mTOR signaling in diabetic nephropathy. , 2015, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[67]  Xiao-Jun Ji,et al.  Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy. , 2015, Pharmacological research.

[68]  E. Bonora,et al.  Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2015, Metabolism: clinical and experimental.

[69]  J. González‐Gallego,et al.  Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy. , 2015, Current medicinal chemistry.

[70]  Chuanzhu Yan,et al.  Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1α pathway. , 2015, Free radical biology & medicine.

[71]  J. Chiang.  Bile acid metabolism and signaling. , 2013, Comprehensive Physiology.

[72]  D. Sabatini,et al.  Regulation of mTORC1 and its impact on gene expression at a glance , 2013, Journal of Cell Science.

[73]  Xiao‐xing Yin,et al.  Protective effects of luteolin on cognitive impairments induced by psychological stress in mice , 2013, Experimental biology and medicine.

[74]  Roy Taylor.  Type 2 Diabetes , 2013, Diabetes Care.

[75]  C. Jung,et al.  Quercetin Reduces High‐Fat Diet‐Induced Fat Accumulation in the Liver by Regulating Lipid Metabolism Genes , 2013, Phytotherapy research : PTR.

[76]  Xiao‐xing Yin,et al.  Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. , 2012, Life sciences.

[77]  P. Puigserver,et al.  Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. , 2012, Cell metabolism.

[78]  Xiao‐xing Yin,et al.  Retracted: Protective Effects of Rutin on Rat Glomerular Mesangial Cells Cultured in High Glucose Conditions , 2011, Phytotherapy research : PTR.

[79]  Xiao‐xing Yin,et al.  In vitro suppression of quercetin on hypertrophy and extracellular matrix accumulation in rat glomerular mesangial cells cultured by high glucose. , 2011, Fitoterapia.

[80]  J. Kountouras,et al.  Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. , 2009, Current molecular medicine.

[81]  G. Marchesini,et al.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? , 2008, Diabetologia.

[82]  G. Lippi,et al.  Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients , 2008, Diabetic medicine : a journal of the British Diabetic Association.